Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Aclaris Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ACRS alerts

About Douglas Manion

Douglas Manion is recorded as Board Member at Aclaris Therapeutics, Inc. (ACRS) since January 1, 2023 and COO at Aclaris Therapeutics, Inc. (ACRS) since August 1, 2022. Aclaris Therapeutics, Inc. reported in an 8-K filed January 19, 2024 that Douglas Manion resigned as Director, effective January 16, 2024. The same filing states: “Dr. Manion's resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.” Aclaris Therapeutics, Inc. reported in an 8-K filed January 19, 2024 that Douglas Manion resigned as Chief Executive Officer and President, effective January 16, 2024. The same filing states: “Dr. Manion's resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.” Aclaris Therapeutics, Inc. reported in an 8-K filed January 6, 2023 that Douglas Manion was appointed Chief Executive Officer, effective January 1, 2023. Equibles holds 6 filed executive changes naming Douglas Manion; each is listed under recent activity with its source filing. The proxy statement of Aclaris Therapeutics, Inc. reports total compensation of $7,157,681 for Douglas Manion in fiscal 2023, including a base salary of $600,000. Disclosed compensation is on record for 2 fiscal years. Douglas Manion has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Aclaris Therapeutics, Inc. on April 14, 2026. Aclaris Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aclaris Therapeutics, Inc. includes Neal Walker (CEO, Chairman and Board Member), Kevin Balthaser (CFO), Douglas Manion, M.D., FRCP (C) (COO) and 4 others.

“On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company's Chief Executive Officer and President and resign from the Board of Directors (the "Board"), effective January 16, 2024.”
“Dr. Manion's resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
Aclaris Therapeutics, Inc. Form 8-K, filed January 19, 2024 · Read the filing
“On January 15, 2024, the Company and Douglas Manion mutually agreed that Dr. Manion will step down as the Company's Chief Executive Officer and President and resign from the Board of Directors (the "Board"), effective January 16, 2024.”
“Dr. Manion's resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.”
Aclaris Therapeutics, Inc. Form 8-K, filed January 19, 2024 · Read the filing

Douglas Manion on recent calls

“Well, I'll start and I'll hand it off to Hugh. But we're really excited about 052. Two, we obviously have already put out SAD-MAD data that show potential for three-month dosing interval and PD effect that would put it in a best-in-class category.”
CEO, H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference ·
“It is my distinct honor to be speaking with you today, following not only my first quarter as CEO, but also the first quarter of operations for our new leadership team.”
CEO, Aclaris Therapeutics, Inc. Q1 FY2023 Earnings Call ·

Affiliation history

Company network

Leadership on record at Aclaris Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2023 Aclaris Therapeutics, Inc. (ACRS) $600,000 $7,157,681
2022 Aclaris Therapeutics, Inc. (ACRS) $204,167 $3,202,198

Recent activity